5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
| Title | Journal |
|---|---|
| Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve. | International journal of cardiology 20150601 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Overview of the new oral anticoagulants: opportunities and challenges. | Arteriosclerosis, thrombosis, and vascular biology 20150501 |
| The role of factor Xa inhibitors in venous thromboembolism treatment. | Vascular health and risk management 20150101 |
| Pharmacology of the new target-specific oral anticoagulants. | Journal of thrombosis and thrombolysis 20130801 |
| Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. | European journal of medicinal chemistry 20130601 |
| A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. | Nature medicine 20130401 |
| Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. | Thrombosis research 20130301 |
| New anticoagulants for treatment of venous thromboembolism. | European journal of internal medicine 20121201 |
| Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice. | Thrombosis research 20121101 |
| Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study. | Thrombosis research 20121101 |
| Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital. | Journal of thrombosis and thrombolysis 20121101 |
| The in vitro anticoagulant effect of rivaroxaban in children. | Thrombosis research 20121101 |
| Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. | British journal of haematology 20121101 |
| Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. | Thrombosis and haemostasis 20121101 |
| Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. | Thrombosis and haemostasis 20121101 |
| Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. | Thrombosis and haemostasis 20121101 |
| The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. | The Journal of bone and joint surgery. British volume 20121101 |
| [New anticoagulants - direct factor Xa-inhibitors]. | Therapeutische Umschau. Revue therapeutique 20121101 |
| [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests]. | Therapeutische Umschau. Revue therapeutique 20121101 |
| [Clinical pharmacological aspects of new oral anticoagulants]. | Therapeutische Umschau. Revue therapeutique 20121101 |
| How I treat anticoagulated patients undergoing an elective procedure or surgery. | Blood 20121011 |
| Oral thromboprophylaxis in pelvic trauma: a standardized protocol. | The Journal of emergency medicine 20121001 |
| For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding. | Evidence-based medicine 20121001 |
| Effects on platelet function of a direct acting antagonist of coagulation factor Xa. | Journal of thrombosis and thrombolysis 20121001 |
| Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001 |
| Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. | PharmacoEconomics 20121001 |
| Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. | QJM : monthly journal of the Association of Physicians 20121001 |
| Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20121001 |
| Anticoagulants in atrial fibrillation patients with chronic kidney disease. | Nature reviews. Nephrology 20121001 |
| Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. | European journal of haematology 20121001 |
| Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. | Journal of thrombosis and haemostasis : JTH 20121001 |
| Atrial fibrillation in long term care. | Journal of the American Medical Directors Association 20121001 |
| Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. | Thrombosis and haemostasis 20121001 |
| New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001 |
| New anticoagulants: A concise review. | The journal of trauma and acute care surgery 20121001 |
| [Prophylaxis of thromboembolic events following hip and knee replacement: dabigatran, rivaroxaban or apixaban in comparison to enoxaparin]. | Der Unfallchirurg 20121001 |
| What did we learn from new oral anticoagulant treatment? | Thrombosis research 20121001 |
| Antithrombotic treatment of atrial fibrillation: new insights. | Thrombosis research 20121001 |
| Do new oral anticoagulants require laboratory monitoring? The clinician point of view. | Thrombosis research 20121001 |
| Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. | Clinical chemistry and laboratory medicine 20121001 |
| The new oral anticoagulants and the future of haemostasis laboratory testing. | Biochemia medica 20121001 |
| Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients. | Cardiovascular journal of Africa 20121001 |
| Oral direct factor Xa inhibitors. | Circulation research 20120928 |
| ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. | Annals of internal medicine 20120918 |
| Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. | The American journal of cardiology 20120915 |
| New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. | Drugs 20120910 |
| Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. | Journal of cardiovascular pharmacology and therapeutics 20120901 |
| Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120901 |
| Antithrombotic options for atrial fibrillation in 2012. | Cardiovascular & hematological disorders drug targets 20120901 |
| Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. | Orthopaedics & traumatology, surgery & research : OTSR 20120901 |
| Treatment of venous thromboembolism with dabigatran. | Current opinion in pulmonary medicine 20120901 |
| Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. | Coronary artery disease 20120901 |
| The management of antithrombotic medication in skin surgery. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20120901 |
| An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. | Thrombosis and haemostasis 20120901 |
| [The ROCKET AF study]. | Giornale italiano di cardiologia (2006) 20120901 |
| Letter to the Editor regarding 'effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma'. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20120901 |
| Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120901 |
| Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. | Circulation. Cardiovascular quality and outcomes 20120901 |
| The novel oral anticoagulants: an update for the interventional radiologist. | AJR. American journal of roentgenology 20120901 |
| [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke]. | Therapeutische Umschau. Revue therapeutique 20120901 |
| Drug interactions with rivaroxaban following total joint replacement surgery. | The Annals of pharmacotherapy 20120901 |
| The promise of novel direct oral anticoagulants. | Best practice & research. Clinical haematology 20120901 |
| Advances in the management of venous thromboembolism. | Best practice & research. Clinical haematology 20120901 |
| Apixaban. After hip or knee replacement: LMWH remains the standard treatment. | Prescrire international 20120901 |
| Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. | Journal of the American College of Cardiology 20120821 |
| Danger ahead: watch out for indirect comparisons! | Journal of the American College of Cardiology 20120821 |
| ACP Journal Club: review: factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement. | Annals of internal medicine 20120821 |
| ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. | Annals of internal medicine 20120821 |
| Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. | Thrombosis research 20120801 |
| A new era of antithrombotic therapy in patients with atrial fibrillation. | The American journal of the medical sciences 20120801 |
| Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. | Thrombosis research 20120801 |
| Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. | The American journal of cardiology 20120801 |
| Novel anticoagulants for non-valvular atrial fibrillation. | Heart, lung & circulation 20120801 |
| Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants? | Current clinical pharmacology 20120801 |
| Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations. | Current clinical pharmacology 20120801 |
| Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants. | Current clinical pharmacology 20120801 |
| Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors. | Journal of cardiothoracic and vascular anesthesia 20120801 |
| Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. | Thrombosis and haemostasis 20120801 |
| Anticoagulation-related intracranial hemorrhages. | Current atherosclerosis reports 20120801 |
| Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. | Thrombosis and haemostasis 20120801 |
| Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. | International angiology : a journal of the International Union of Angiology 20120801 |
| Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? | The Lancet. Neurology 20120801 |
| [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients]. | Zeitschrift fur Gerontologie und Geriatrie 20120801 |
| Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. | Minerva cardioangiologica 20120801 |
| Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. | Expert review of cardiovascular therapy 20120801 |
| Periprocedural anticoagulant management. | Hospital practice (1995) 20120801 |
| The new oral anticoagulants: a challenge for hospital formularies. | Hospital practice (1995) 20120801 |
| New oral anticoagulants for atrial fibrillation. | Circulation 20120703 |
| Renal profiles of anticoagulants. | Journal of clinical pharmacology 20120701 |
| Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. | British journal of clinical pharmacology 20120701 |
| Pharmacologic and nonpharmacologic therapies for stroke prevention in nonvalvular atrial fibrillation. | Pacing and clinical electrophysiology : PACE 20120701 |
| Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. | Thrombosis and haemostasis 20120701 |
| Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. | Expert opinion on drug metabolism & toxicology 20120701 |
| New drugs 2012, part 2. | Nursing 20120701 |
| Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. | Circulation. Cardiovascular quality and outcomes 20120701 |
| Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. | Future cardiology 20120701 |
| Pneumococcal vaccines; use of rivaroxaban for DVT and PE. | JAAPA : official journal of the American Academy of Physician Assistants 20120701 |
| Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. | Journal of thrombosis and haemostasis : JTH 20120701 |
| Oral rivaroxaban for pulmonary embolism. | The New England journal of medicine 20120628 |
| Oral rivaroxaban for pulmonary embolism. | The New England journal of medicine 20120628 |
| Oral rivaroxaban for pulmonary embolism. | The New England journal of medicine 20120628 |
| Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. | Drugs 20120618 |
| New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors. | Current drug discovery technologies 20120601 |
| Discovery of anticoagulant drugs: a historical perspective. | Current drug discovery technologies 20120601 |
| Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban). | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20120601 |
| The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. | Thrombosis and haemostasis 20120601 |
| Novel oral anticoagulants after acute coronary syndromes. | Cardiovascular drugs and therapy 20120601 |
| Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. | Thrombosis and haemostasis 20120601 |
| New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. | Journal of internal medicine 20120601 |
| Novel antithrombotic agents for atrial fibrillation. | Pharmacology & therapeutics 20120601 |
| Long-term benefits of preventing venous thromboembolic events. | Current medical research and opinion 20120601 |
| [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring]. | Herz 20120601 |
| [Pharmacology of the new oral anticoagulants]. | Herz 20120601 |
| [Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice]. | Herz 20120601 |
| [Anticoagulation. Modern concepts]. | Herz 20120601 |
| Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. | Critical pathways in cardiology 20120601 |
| A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. | Critical pathways in cardiology 20120601 |
| The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. | Expert opinion on therapeutic patents 20120601 |
| Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. | Advances in therapy 20120601 |
| Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis. | Orthopedics 20120601 |
| Efficacy of extramedullary femoral component alignment guide system for blood saving after total knee arthroplasty. | Knee surgery & related research 20120601 |
| Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs. | Discovery medicine 20120601 |
| Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery. | The Nurse practitioner 20120511 |
| Anticoagulant therapy for patients with ischaemic stroke. | Nature reviews. Neurology 20120508 |
| Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. | Nature reviews. Cardiology 20120508 |
| Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. | Drugs 20120507 |
| Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. | European journal of clinical pharmacology 20120501 |
| Tissue factor-driven thrombin generation and inflammation in atherosclerosis. | Thrombosis research 20120501 |
| Reversal of antithrombotic agents. | American journal of hematology 20120501 |
| Advances in laboratory testing for thrombophilia. | American journal of hematology 20120501 |
| Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. | American journal of hematology 20120501 |
| Implementing the new oral anticoagulants into the hospital formulary. | American journal of hematology 20120501 |
| Prevention of venous thromboembolism in total knee and hip replacement. | Circulation 20120501 |
| Novel oral anticoagulants--key messages for the angiologist. | VASA. Zeitschrift fur Gefasskrankheiten 20120501 |
| New oral anticoagulants: will they replace warfarin? | Oral surgery, oral medicine, oral pathology and oral radiology 20120501 |
| Oral anticoagulants for atrial fibrillation: Which one to choose? | Advance for NPs & PAs 20120501 |
| Newer oral anticoagulant agents: a new era in medicine. | Current cardiology reviews 20120501 |
| Letter by Bernstein et al regarding article, 'reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. | Circulation 20120424 |
| Letter by Marlu et al regarding article, 'reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects'. | Circulation 20120424 |
| [Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy]. | MMW Fortschritte der Medizin 20120419 |
| New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. | Journal of the American College of Cardiology 20120417 |
| Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. | Circulation 20120410 |
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. | The New England journal of medicine 20120405 |
| Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. | Thrombosis research 20120401 |
| Novel anticoagulants for atrial fibrillation: a critical appraisal. | Angiology 20120401 |
| Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement? | Acta orthopaedica 20120401 |
| Rivaroxaban and recurrent stroke prevention in AF. | The Lancet. Neurology 20120401 |
| Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. | The Lancet. Neurology 20120401 |
| New oral anticoagulants for atrial fibrillation: a review of clinical trials. | Clinical therapeutics 20120401 |
| Rivaroxaban: a new oral anticoagulant. | Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 20120401 |
| Preventing venous thromboembolic events after total hip arthroplasty: new developments in clinical practice. | Hospital practice (1995) 20120401 |
| Thromboprophylaxis in surgical and medical patients. | Seminars in respiratory and critical care medicine 20120401 |
| Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. | Oral surgery, oral medicine, oral pathology and oral radiology 20120401 |
| How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. | Blood 20120329 |
| [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?]. | MMW Fortschritte der Medizin 20120322 |
| Rivaroxaban vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. | American family physician 20120315 |
| Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. | Thrombosis and haemostasis 20120301 |
| Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. | Thrombosis research 20120301 |
| Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. | Biopharmaceutics & drug disposition 20120301 |
| What's the 'go to' anticoagulant for stroke prevention in atrial fibrillation? | Thrombosis and haemostasis 20120301 |
| New directions in anticoagulation. | The American journal of medicine 20120301 |
| A new generation of oral direct anticoagulants. | Arteriosclerosis, thrombosis, and vascular biology 20120301 |
| Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120301 |
| Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. | Expert review of cardiovascular therapy 20120301 |
| Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. | Seminars in thrombosis and hemostasis 20120301 |
| Determination of rivaroxaban in human plasma samples. | Seminars in thrombosis and hemostasis 20120301 |
| The efficacy and safety of postoperative autologous transfusion of filtered shed blood and anticoagulant prophylaxis in total knee arthroplasty patients. | Knee surgery & related research 20120301 |
| Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. | Nature reviews. Cardiology 20120227 |
| Oral factor Xa inhibitors for the long-term management of ACS. | Nature reviews. Cardiology 20120221 |
| Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. | Blood 20120202 |
| Anticoagulant management in the cardiovascular setting. | Fundamental & clinical pharmacology 20120201 |
| Pharmacodynamic and pharmacokinetic basics of rivaroxaban. | Fundamental & clinical pharmacology 20120201 |
| Rivaroxaban for the prevention and treatment of venous thromboembolism. | Fundamental & clinical pharmacology 20120201 |
| New anticoagulants for the prevention of stroke in atrial fibrillation. | Fundamental & clinical pharmacology 20120201 |
| Lack of an antagonist to reverse the action of dabigatran. | QJM : monthly journal of the Association of Physicians 20120201 |
| Management of coagulation: an Australian perspective. | Current opinion in anaesthesiology 20120201 |
| Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. | Thrombosis and haemostasis 20120201 |
| Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. | PharmacoEconomics 20120201 |
| Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. | Journal of cardiovascular medicine (Hagerstown, Md.) 20120201 |
| The year in Cardiothoracic and Vascular Anesthesia: selected highlights from 2011. | Journal of cardiothoracic and vascular anesthesia 20120201 |
| The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? | International journal of stroke : official journal of the International Stroke Society 20120201 |
| Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. | Expert review of hematology 20120201 |
| Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20120201 |
| Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. | Expert review of neurotherapeutics 20120201 |
| Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. | Seminars in thrombosis and hemostasis 20120201 |
| Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | Chest 20120201 |
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | Chest 20120201 |
| Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | Chest 20120201 |
| [Expanded arsenal in atrial fibrillation: bye-bye marcumar?]. | MMW Fortschritte der Medizin 20120119 |
| Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF. | Annals of internal medicine 20120117 |
| Rivaroxaban in patients with a recent acute coronary syndrome. | The New England journal of medicine 20120105 |
| A new era in secondary prevention after acute coronary syndrome. | The New England journal of medicine 20120105 |
| New anticoagulants - promising and failed developments. | British journal of pharmacology 20120101 |
| Novel oral anticoagulants: new challenges for anesthesiologists in bleeding patients. | Anesthesiology 20120101 |
| Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. | Thrombosis research 20120101 |
| Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. | Anesthesiology 20120101 |
| Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation. | Journal of neurology 20120101 |
| [Anticoagulation in atrial fibrillation: a new era has begun]. | Hamostaseologie 20120101 |
| [Anticoagulation for atrial fibrillation : the future has begun]. | Der Internist 20120101 |
| Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. | The Journal of bone and joint surgery. British volume 20120101 |
| [Apixaban: pharmacology and action profile]. | Deutsche medizinische Wochenschrift (1946) 20120101 |
| New frontiers for stroke prevention in atrial fibrillation. | Cerebrovascular diseases (Basel, Switzerland) 20120101 |
| [Summary of the article: Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 1557-1559]. | Kardiologia polska 20120101 |
| ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? | Cardiology journal 20120101 |
| New antiplatelet and anticoagulant drugs. | General dentistry 20120101 |
| Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. | Postgraduate medicine 20120101 |
| New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. | Vascular health and risk management 20120101 |
| I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different? | DukeMedicine healthnews 20120101 |
| A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation? | Polskie Archiwum Medycyny Wewnetrznej 20120101 |
| Newer anticoagulants in cardiovascular disease: a systematic review of the literature. | Cardiology in review 20120101 |
| Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review. | Connecticut medicine 20120101 |
| Improving prevention and treatment of venous thromboembolism: clinical trial results. | Journal of medical economics 20120101 |
| Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120101 |
| The WATCHMAN left atrial appendage closure device for atrial fibrillation. | Journal of visualized experiments : JoVE 20120101 |
| Stroke Prevention in Atrial Fibrillation: Where are We Now? | Clinical Medicine Insights. Cardiology 20120101 |
| Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. | The Canadian journal of cardiology 20120101 |
| [Update on current care guidelines: atrial fibrillation]. | Duodecim; laaketieteellinen aikakauskirja 20120101 |
| Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. | Journal of medical economics 20120101 |
| The Anticoagulation of Calf Thrombosis (ACT) project: study protocol for a randomized controlled trial. | Trials 20120101 |
| Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. | Journal of medical economics 20120101 |
| Current status of new anticoagulants in the management of venous thromboembolism. | Advances in hematology 20120101 |
| Costs and clinical consequences of suboptimal atrial fibrillation management. | ClinicoEconomics and outcomes research : CEOR 20120101 |
| The Interface between Inflammation and Coagulation in Cardiovascular Disease. | International journal of inflammation 20120101 |
| Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. | Therapeutics and clinical risk management 20120101 |
| Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban. | Reviews in cardiovascular medicine 20120101 |
| The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. | ClinicoEconomics and outcomes research : CEOR 20120101 |
| Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. | Journal of blood medicine 20120101 |
| Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. | Thrombosis 20120101 |
| Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report. | Journal of medical case reports 20120101 |
| [New antithrombotic drugs]. | Duodecim; laaketieteellinen aikakauskirja 20120101 |
| Advances in the diagnosis and treatment of acute pulmonary embolism. | F1000 medicine reports 20120101 |
| Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011. | Open medicine : a peer-reviewed, independent, open-access journal 20120101 |
| Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. | PloS one 20120101 |
| Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging 'real-world' questions. | Thrombosis 20120101 |
| Newer anticoagulants for the prevention of venous thromboembolism. | The National medical journal of India 20120101 |
| Emerging anticoagulants. | Current medicinal chemistry 20120101 |
| Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. | BMJ (Clinical research ed.) 20120101 |
| Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. | Vascular health and risk management 20120101 |
| Health technology assessment and its role in the future development of the Indian healthcare sector. | Perspectives in clinical research 20120101 |
| [Rivaroxaban in the prevention and treatment of thromboembolic disorders]. | Hamostaseologie 20120101 |
| [New anticoagulants: dabigatran, rivaroxaban and apixaban]. | Gaceta medica de Mexico 20120101 |
| An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. | Core evidence 20120101 |
| Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. | Current medicinal chemistry 20120101 |
| Perioperative stroke risk in nonvascular surgery. | Cerebrovascular diseases (Basel, Switzerland) 20120101 |
| Vitamin K antagonists. Ready to be replaced? | Hamostaseologie 20120101 |
| Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis. | Orthopedic nursing 20120101 |
| Rivaroxaban in atrial fibrillation. | Vascular health and risk management 20120101 |
| Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective. | Polskie Archiwum Medycyny Wewnetrznej 20120101 |
| Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. | Thrombosis 20120101 |
| [New oral anticoagulants for atrial fibrillation: a neurologist's view]. | Nederlands tijdschrift voor geneeskunde 20120101 |
| Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? | Thrombosis 20120101 |
| Thromboembolic prophylaxis in total joint arthroplasty. | Thrombosis 20120101 |
| Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. | BMJ open 20120101 |
| [Therapeutic approach to the bleeding in association with 'old' and 'new' anticoagulants]. | Vnitrni lekarstvi 20120101 |
| [Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis]. | Hamostaseologie 20120101 |
| Left atrial appendage exclusion for stroke prevention in atrial fibrillation. | Cardiology research and practice 20120101 |
| Rationalizing tight ligand binding through cooperative interaction networks. | Journal of chemical information and modeling 20111227 |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | The New England journal of medicine 20111215 |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | The New England journal of medicine 20111215 |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | The New England journal of medicine 20111215 |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | The New England journal of medicine 20111215 |
| Rivaroxaban (Xarelto) for acute coronary syndrome. | The Medical letter on drugs and therapeutics 20111212 |
| Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. | Journal of medicinal chemistry 20111208 |
| Antiplatelet agents and anticoagulants for hypertension. | The Cochrane database of systematic reviews 20111207 |
| Drugs in traffic: the road to approval. | Nature medicine 20111206 |
| Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. | Journal of cardiovascular pharmacology 20111201 |
| New anticoagulants: moving on from scientific results to clinical implementation. | Annals of medicine 20111201 |
| Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111201 |
| Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111201 |
| Intraarticular vs. extraarticular ropivacaine infusion following high-dose local infiltration analgesia after total knee arthroplasty: a randomized double-blind study. | Acta orthopaedica 20111201 |
| [Stabilization of inter- and subtrochanteric femoral fractures with the PFNΑ®]. | Operative Orthopadie und Traumatologie 20111201 |
| Laboratory testing of anticoagulants: the present and the future. | Pathology 20111201 |
| [Thrombosis prophylaxis in surgery. What is the evidence?]. | Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20111201 |
| Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review. | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20111201 |
| Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. | Pharmacotherapy 20111201 |
| [Pharmacologic heterogeneity of new anticoagulants]. | Journal des maladies vasculaires 20111201 |
| [New treatments for venous thromboembolic disease]. | Journal des maladies vasculaires 20111201 |
| [Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects]. | MMW Fortschritte der Medizin 20111201 |
| [Rivaroxaban is not inferior compared with warfarin as an anticoagulant in patients with non-valvular atrial fibrillation]. | Praxis 20111130 |
| Acute coronary syndromes: Rivaroxaban reduces serious CV events without increasing fatal bleeding in patients with a recent ACS. | Nature reviews. Cardiology 20111129 |
| FDA advisory decision highlights some problems inherent in pragmatic trials. | JAMA 20111102 |
| Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. | Current vascular pharmacology 20111101 |
| Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. | Journal of thrombosis and thrombolysis 20111101 |
| Rationale and current perspective for early rhythm control therapy in atrial fibrillation. | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20111101 |
| Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. | Thrombosis and haemostasis 20111101 |
| [New anticoagulants. Characteristics, monitoring and management of bleeding]. | Medizinische Klinik, Intensivmedizin und Notfallmedizin 20111101 |
| A study of thromboprophylactic practices of Scottish orthopaedic surgeons in patients undergoing total hip replacements. Should practice change with new guidelines? | Scottish medical journal 20111101 |
| [Effect of rivaroxaban on risk of bleeding after total knee arthroplasty]. | Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 20111101 |
| [Current status and future of anti-Xa inhibitors]. | Rinsho shinkeigaku = Clinical neurology 20111101 |
| [New anticoagulants]. | La Revue du praticien 20111101 |
| Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. | The New England journal of medicine 20111027 |
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. | Circulation 20111004 |
| Reversal of new oral anticoagulants. | Circulation 20111004 |
| Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. | Evidence-based medicine 20111001 |
| Inhibitors of propagation of coagulation: factors V and X. | British journal of clinical pharmacology 20111001 |
| A role for coagulation factor Xa in experimental pulmonary arterial hypertension. | Cardiovascular research 20111001 |
| New anticoagulants: how to deal with treatment failure and bleeding complications. | British journal of clinical pharmacology 20111001 |
| Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. | Canadian journal of surgery. Journal canadien de chirurgie 20111001 |
| Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111001 |
| Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. | Journal of thrombosis and thrombolysis 20111001 |
| Anticoagulating obese patients in the modern era. | British journal of haematology 20111001 |
| Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. | European heart journal 20111001 |
| RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. | European heart journal 20111001 |
| Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. | Clinical pharmacokinetics 20111001 |
| New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. | Pharmacotherapy 20111001 |
| Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. | Orthopedics 20111001 |
| Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. | Expert review of pharmacoeconomics & outcomes research 20111001 |
| Dutch guideline on total hip prosthesis. | Acta orthopaedica 20111001 |
| The new oral anticoagulants. | Clinical medicine (London, England) 20111001 |
| Xarelto: a new drug for new joints. Hip and knee recipients can avoid postsurgical clots without undergoing painful injections. | The Johns Hopkins medical letter health after 50 20111001 |
| [New antithrombotic drugs for the treatment of venous thromboembolism]. | Revue des maladies respiratoires 20111001 |
| [Atrial fibrillation: what the GP needs to know]. | MMW Fortschritte der Medizin 20110922 |
| [Modern risk assessment and stroke prevention in atrial fibrillation]. | Praxis 20110921 |
| A new era for anticoagulation in atrial fibrillation. | The New England journal of medicine 20110915 |
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. | The New England journal of medicine 20110908 |
| New options in anticoagulation for atrial fibrillation. | The New England journal of medicine 20110908 |
| Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. | Expert opinion on drug safety 20110901 |
| Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. | Blood reviews 20110901 |
| Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. | Journal of thrombosis and haemostasis : JTH 20110901 |
| Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells. | Thrombosis and haemostasis 20110901 |
| Update on anti-coagulation in atrial fibrillation. | QJM : monthly journal of the Association of Physicians 20110901 |
| [Thromboembolic prophylaxis 2011: is warfarin on the wane?]. | Giornale italiano di cardiologia (2006) 20110901 |
| Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis. | British journal of hospital medicine (London, England : 2005) 20110901 |
| Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. | Seminars in vascular surgery 20110901 |
| Rivaroxaban (Xarelto)--a new oral anticoagulant. | The Medical letter on drugs and therapeutics 20110822 |
| New antithrombotic drugs and European approval processes. | Lancet (London, England) 20110820 |
| Oral direct factor Xa inhibitor gets FDA's OK. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110815 |
| Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. | Journal of medicinal chemistry 20110811 |
| [The new Anticoagulants - Relevant Facts for the GP]. | Praxis 20110810 |
| [Rivaroxaban as therapy of deep venous thrombosis equally as effective as current anticoagulation with heparin and vitamin K antagonist]. | Praxis 20110810 |
| ['Xa-tra-xa': opportunities and open questions about new anticoagulants]. | Praxis 20110810 |
| Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. | European heart journal 20110801 |
| Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. | Journal of thrombosis and haemostasis : JTH 20110801 |
| New anticoagulants for prevention of stroke in patients with atrial fibrillation. | Journal of cardiovascular electrophysiology 20110801 |
| Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. | Journal of thrombosis and haemostasis : JTH 20110801 |
| Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801 |
| New oral anticoagulants for venous thromboembolism (VTE) prophylaxis. | The Medical journal of Malaysia 20110801 |
| Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban. | American journal of therapeutics 20110701 |
| In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. | The Journal of pharmacology and experimental therapeutics 20110701 |
| Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. | Current opinion in cardiology 20110701 |
| Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. | Thrombosis and haemostasis 20110701 |
| Response to 'Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban'. | Journal of clinical pharmacology 20110701 |
| Practical aspects of the oral new anticoagulants. | American journal of hematology 20110701 |
| Treatment of risk factors to prevent stroke. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20110701 |
| Optimal duration of anticoagulation in patients with venous thromboembolism. | The Indian journal of medical research 20110701 |
| Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). | Expert review of cardiovascular therapy 20110701 |
| [New anticoagulants in the prevention and treatment of venous thromboembolism]. | Orvosi hetilap 20110619 |
| The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. | Thrombosis research 20110601 |
| Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding. | Current treatment options in cardiovascular medicine 20110601 |
| Treating arrhythmias: an expert opinion. | Expert opinion on pharmacotherapy 20110601 |
| A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. | Thrombosis research 20110601 |
| Rivaroxaban in the contemporary treatment of acute coronary syndromes. | Expert opinion on investigational drugs 20110601 |
| Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. | Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing 20110601 |
| Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. | International angiology : a journal of the International Union of Angiology 20110601 |
| Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. | Expert review of pharmacoeconomics & outcomes research 20110601 |
| 4-(3-Fluoro-4-nitro-phen-yl)morpholin-3-one. | Acta crystallographica. Section E, Structure reports online 20110601 |
| [Is the era from the end of warfarin?]. | Medizinische Monatsschrift fur Pharmazeuten 20110601 |
| ACP journal club. Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment. | Annals of internal medicine 20110517 |
| Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer? | Current vascular pharmacology 20110501 |
| Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease? | Reviews on recent clinical trials 20110501 |
| Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. | Thrombosis research 20110501 |
| Laboratory assessment of new anticoagulants. | Clinical chemistry and laboratory medicine 20110501 |
| Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. | Journal of thrombosis and thrombolysis 20110501 |
| Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. | Journal of thrombosis and thrombolysis 20110501 |
| Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap? | Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20110501 |
| Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. | American heart journal 20110501 |
| [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. | Medecine sciences : M/S 20110501 |
| Advances in cardiology: clinical trial update. | Future cardiology 20110501 |
| [The new anticoagulants]. | Harefuah 20110501 |
| [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation]. | MMW Fortschritte der Medizin 20110414 |
| Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. | Blood 20110407 |
| A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. | Cancer chemotherapy and pharmacology 20110401 |
| The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. | Pharmacology & therapeutics 20110401 |
| Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? | Thrombosis and haemostasis 20110401 |
| What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? | Thrombosis and haemostasis 20110401 |
| New oral anticoagulants. | Journal of thrombosis and thrombolysis 20110401 |
| Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. | Journal of thrombosis and thrombolysis 20110401 |
| Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. | Expert opinion on investigational drugs 20110401 |
| Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. | European journal of heart failure 20110401 |
| Preventing postsurgical venous thromboembolism: pharmacological approaches. | Seminars in thrombosis and hemostasis 20110401 |
| Oral rivaroxaban for symptomatic venous thromboembolism. | The New England journal of medicine 20110324 |
| Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. | Thrombosis and haemostasis 20110301 |
| Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. | Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20110301 |
| Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. | Expert opinion on pharmacotherapy 20110301 |
| Old and new anticoagulant drugs: a minireview. | Annals of medicine 20110301 |
| Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. | Drugs & aging 20110301 |
| Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. | Drug safety 20110301 |
| The discovery and development of rivaroxaban. | Annals of the New York Academy of Sciences 20110301 |
| Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20110201 |
| Rivaroxaban and false positive lupus anticoagulant testing. | Thrombosis and haemostasis 20110201 |
| New anticoagulant agents in acute coronary syndromes. | Heart (British Cardiac Society) 20110201 |
| Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. | Journal of clinical pharmacy and therapeutics 20110201 |
| Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. | Phlebology 20110201 |
| [New oral anticoagulants in atrial fibrillation]. | Der Nervenarzt 20110201 |
| Association of warfarin use with valvular and vascular calcification: a review. | Clinical cardiology 20110201 |
| Old and new anticoagulants. | Hamostaseologie 20110201 |
| New anticoagulants: pharmacology and clinical studies. | Wiener medizinische Wochenschrift (1946) 20110201 |
| Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. | Wiener medizinische Wochenschrift (1946) 20110201 |
| New oral anticoagulants and outpatient prophylaxis of venous thromboembolism. | The American journal of managed care 20110201 |
| Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. | The American journal of managed care 20110201 |
| Characteristics of novel anticoagulants and potential economic implications. | The American journal of managed care 20110201 |
| Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue. | The American journal of managed care 20110201 |
| Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. | The American journal of managed care 20110201 |
| New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. | BMJ (Clinical research ed.) 20110118 |
| New alternative to warfarin may help reduce stroke risk in patients with AF. | JAMA 20110105 |
| The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. | Journal of thrombosis and haemostasis : JTH 20110101 |
| Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. | Journal of thrombosis and haemostasis : JTH 20110101 |
| Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins. | Analytical and bioanalytical chemistry 20110101 |
| Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery. | Current vascular pharmacology 20110101 |
| The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. | Nature reviews. Drug discovery 20110101 |
| Factor Xa and thrombin as targets for new oral anticoagulants. | Thrombosis research 20110101 |
| Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. | The Journal of bone and joint surgery. British volume 20110101 |
| Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. | Annual review of medicine 20110101 |
| New oral anticoagulants: should they replace heparins and warfarin? | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20110101 |
| An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. | Journal of medical economics 20110101 |
| Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. | Patient preference and adherence 20110101 |
| [Perioperative venous thromboembolism prophylaxis]. | La Revue du praticien 20110101 |
| Heparin-induced thrombocytopenia in the ICU: an overview. | Critical care (London, England) 20110101 |
| The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. | Vascular health and risk management 20110101 |
| Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. | PloS one 20110101 |
| New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery. | Instructional course lectures 20110101 |
| Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation? | Cardiology research and practice 20110101 |
| Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare. | Implementation science : IS 20110101 |
| [Drug prevention of pulmonary embolism in orthopedic practice: traditional and novel approaches]. | Kardiologiia 20110101 |
| Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. | BMJ (Clinical research ed.) 20110101 |
| Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. | Mediators of inflammation 20110101 |
| Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. | Thrombosis journal 20110101 |
| Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. | Vascular health and risk management 20110101 |
| Antithrombotic medication for cardioembolic stroke prevention. | Stroke research and treatment 20110101 |
| Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. | BMC family practice 20110101 |
| Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. | Journal of pregnancy 20110101 |
| FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery. | Cardiovascular journal of Africa 20110101 |
| Evaluation of marine brown algae and sponges from Brazil as anticoagulant and antiplatelet products. | Marine drugs 20110101 |
| Anesthesia for joint replacement surgery: Issues with coexisting diseases. | Journal of anaesthesiology, clinical pharmacology 20110101 |
| Tissue factor, blood coagulation, and beyond: an overview. | International journal of inflammation 20110101 |
| Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient. | Advances in surgery 20110101 |
| [The new oral anticoagulants in surgery]. | Revista medica del Instituto Mexicano del Seguro Social 20110101 |
| European Society of Cardiology congress 2011. | Cardiovascular journal of Africa 20110101 |
| Role of factor xa inhibitors in cancer-associated thrombosis: any new data? | Advances in hematology 20110101 |
| Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. | Journal of medical economics 20110101 |
| Emerging therapies for acute coronary syndromes. | Frontiers in pharmacology 20110101 |
| The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. | BMC musculoskeletal disorders 20110101 |
| Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. | BMJ (Clinical research ed.) 20110101 |
| Rivaroxaban, ticagrelor, and fidaxomicin. | Journal of the American Pharmacists Association : JAPhA 20110101 |
| Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement. | Thrombosis 20110101 |
| Venous thromboembolism: classification, risk factors, diagnosis, and management. | ISRN hematology 20110101 |
| Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. | Thrombosis journal 20110101 |
| Anticoagulants and the propagation phase of thrombin generation. | PloS one 20110101 |
| Gene-drug interaction in stroke. | Stroke research and treatment 20110101 |
| Raft of rivaroxaban good news from the USA, implications for South African clinical practice. | Cardiovascular journal of Africa 20110101 |
| Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. | International journal of nanomedicine 20110101 |
| Cardiac arrest caused by multiple recurrent pulmonary embolism. | Case reports in medicine 20110101 |
| Pharmacological basis and clinical evidence of dabigatran therapy. | Journal of hematology & oncology 20110101 |
| The case for an elderly targeted stroke management. | Frontiers in neurology 20110101 |
| Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate. | The open orthopaedics journal 20110101 |
| Deep vein thrombosis: a clinical review. | Journal of blood medicine 20110101 |
| Oral rivaroxaban for symptomatic venous thromboembolism. | The New England journal of medicine 20101223 |
| Therapeutic potential of oral factor Xa inhibitors. | The New England journal of medicine 20101223 |
| Engineered thrombin aims to take on heparin. | Chemistry & biology 20101222 |
| Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. | Journal of the American College of Cardiology 20101214 |
| [Rivaroxaban at least as effective as marcumar in stroke prevention]. | MMW Fortschritte der Medizin 20101202 |
| [New oral anticoagulants: better than vitamin K antagonists?]. | Der Internist 20101201 |
| Assays for measuring rivaroxaban: their suitability and limitations. | Therapeutic drug monitoring 20101201 |
| The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery? | Current opinion in anaesthesiology 20101201 |
| The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. | British journal of haematology 20101201 |
| Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. | Thrombosis and haemostasis 20101201 |
| New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. | Clinics in chest medicine 20101201 |
| Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem? | Acta clinica Croatica 20101201 |
| Clinical pharmacology of direct and indirect factor Xa inhibitors. | Drugs 20101112 |
| Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey. | Annals of the Royal College of Surgeons of England 20101101 |
| An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. | Thrombosis and haemostasis 20101101 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. | European journal of clinical pharmacology 20101101 |
| Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. | Circulation. Cardiovascular quality and outcomes 20101101 |
| Blood transfusion and the anaesthetist: management of massive haemorrhage. | Anaesthesia 20101101 |
| [Prophylaxis of thrombembolic diseases with rivaroxaban]. | Deutsche medizinische Wochenschrift (1946) 20101101 |
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. | British journal of clinical pharmacology 20101101 |
| Korean guidelines for the prevention of venous thromboembolism. | Journal of Korean medical science 20101101 |
| [Novel anticoagulants for stroke prevention in atrial fibrillation]. | Deutsche medizinische Wochenschrift (1946) 20101101 |
| [New oral anticoagulants from the perspective of trauma surgery]. | Der Unfallchirurg 20101101 |
| [Thromboembolism prophylaxis in trauma surgery: S3 guidelines and significance of the amendment for trauma surgeons]. | Der Unfallchirurg 20101101 |
| [Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology]. | Der Unfallchirurg 20101101 |
| [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems]. | Annales pharmaceutiques francaises 20101101 |
| [New study findings in cardiology. The best is the enemy of the good]. | Medizinische Monatsschrift fur Pharmazeuten 20101101 |
| New options for stroke prevention in atrial fibrillation. | The American journal of managed care 20101101 |
| Rivaroxaban: a novel anticoagulant. | Indian journal of medical sciences 20101101 |
| New antithrombotics for atrial fibrillation. | Cardiovascular therapeutics 20101001 |
| Emerging antithrombotic agents: what does the intensivist need to know? | Current opinion in critical care 20101001 |
| Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. | Thrombosis and haemostasis 20101001 |
| Low risk of thromboembolic complications after fast-track hip and knee arthroplasty. | Acta orthopaedica 20101001 |
| Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery. | Anaesthesia 20101001 |
| Factor Xa inhibitors: next-generation antithrombotic agents. | Journal of medicinal chemistry 20100909 |
| Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. | Journal of clinical pharmacology 20100901 |
| [Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ]. | Zeitschrift fur Orthopadie und Unfallchirurgie 20100901 |
| New antithrombotic agents--insights from clinical trials. | Nature reviews. Cardiology 20100901 |
| Novel oral anticoagulants: implications in the perioperative setting. | Anesthesiology 20100901 |
| [Rivaroxaban and factor Xa inhibitors in clinical practice]. | Vnitrni lekarstvi 20100901 |
| Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. | Journal of cardiovascular pharmacology 20100801 |
| Anticoagulation by factor Xa inhibitors. | Journal of thrombosis and haemostasis : JTH 20100801 |
| Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. | Thrombosis and haemostasis 20100801 |
| Treatment of thromboembolism in cancer patients. | Expert opinion on pharmacotherapy 20100801 |
| Oral Xa inhibitors. | Hematology/oncology clinics of North America 20100801 |
| [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801 |
| Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. | Current opinion in cardiology 20100701 |
| New oral anticoagulant drugs in cardiovascular disease. | Thrombosis and haemostasis 20100701 |
| Clot prevention--common questions about medications. | Australian family physician 20100701 |
| [A new deal with new anticoagulants?]. | Journal des maladies vasculaires 20100601 |
| Old versus new anticoagulants: focus on pharmacology. | Recent patents on cardiovascular drug discovery 20100601 |
| Anesthetic concerns for patients with coagulopathy. | Current opinion in anaesthesiology 20100601 |
| Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. | The Annals of pharmacotherapy 20100601 |
| Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery. | Anaesthesia 20100601 |
| Drug and dietary interactions of the new and emerging oral anticoagulants. | International journal of clinical practice 20100601 |
| Novel oral anticoagulants. Part II: direct thrombin inhibitors. | Expert review of hematology 20100601 |
| [New oral anticoagulants: prospects]. | La Revue du praticien 20100520 |
| Emerging anticoagulants for venous thromboembolism prevention. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515 |
| New anticoagulants for prevention and treatment of venous thromboembolism. | Current vascular pharmacology 20100501 |
| Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. | Archives of orthopaedic and trauma surgery 20100501 |
| New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100501 |
| Primary prevention of venous thromboembolism in medical and surgical oncology patients. | British journal of cancer 20100413 |
| Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. | Thrombosis and haemostasis 20100401 |
| Facts and artefacts of coagulation assays for factor Xa inhibitors. | Thrombosis and haemostasis 20100401 |
| Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? | Lupus 20100401 |
| Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. | Croatian medical journal 20100401 |
| VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. | Thrombosis research 20100401 |
| Potential of new anticoagulants in patients with cancer. | Thrombosis research 20100401 |
| Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). | Expert review of hematology 20100401 |
| Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. | Thrombosis and haemostasis 20100301 |
| DVT: a new era in anticoagulant therapy. | Arteriosclerosis, thrombosis, and vascular biology 20100301 |
| Rivaroxaban: a new oral factor Xa inhibitor. | Arteriosclerosis, thrombosis, and vascular biology 20100301 |
| Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. | The Lancet. Neurology 20100301 |
| Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. | American heart journal 20100301 |
| Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. | The Journal of bone and joint surgery. British volume 20100301 |
| Recent advances in the management of venous thromboembolism. | The Korean journal of hematology 20100301 |
| New oral anticoagulants: a practical guide for clinicians. | Journal of thrombosis and thrombolysis 20100201 |
| The ultimate anticoagulants? | Cardiovascular journal of Africa 20100201 |
| [Update on new antithrombotic treatments]. | Revue medicale suisse 20100120 |
| The new oral anticoagulants. | Blood 20100107 |
| Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. | Current vascular pharmacology 20100101 |
| Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. | Thrombosis and haemostasis 20100101 |
| The potential benefits of low-molecular-weight heparins in cancer patients. | Journal of hematology & oncology 20100101 |
| [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential]. | Zeitschrift fur Orthopadie und Unfallchirurgie 20100101 |
| Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). | Current topics in medicinal chemistry 20100101 |
| New oral anticoagulants in development: potential for improved safety profiles. | Reviews in neurological diseases 20100101 |
| Forecasting drug utilization and expenditure in a metropolitan health region. | BMC health services research 20100101 |
| New options with dabigatran etexilate in anticoagulant therapy. | Vascular health and risk management 20100101 |
| New anticoagulants for the prevention of venous thromboembolism. | Drug design, development and therapy 20100101 |
| Deep vein thrombosis and pulmonary embolism - Prevention, management, and anaesthetic considerations. | Indian journal of anaesthesia 20100101 |
| Novel anticoagulant therapy: principle and practice. | Methods in molecular biology (Clifton, N.J.) 20100101 |
| Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. | Methods in molecular biology (Clifton, N.J.) 20100101 |
| [Anticoagulant therapy in cardiology: yesterday, today, tomorrow]. | Kardiologiia 20100101 |
| Prevention strategies for cardioembolic stroke: present and future perspectives. | The open neurology journal 20100101 |
| Oral anticoagulants in pediatric cardiac practice: A systematic review of the literature. | Annals of pediatric cardiology 20100101 |
| Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. | PharmacoEconomics 20100101 |
| Further issues with new oral anticoagulants. | Current pharmaceutical design 20100101 |
| New anticoagulants for the prevention of thromboembolism. | Current pharmaceutical design 20100101 |
| Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. | Current pharmaceutical design 20100101 |
| Managing bleeding complications in patients treated with the old and the new anticoagulants. | Current pharmaceutical design 20100101 |
| Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice. | F1000 medicine reports 20100101 |
| Effective single-drug approach is welcomed for deep-vein thrombosis treatment. | Cardiovascular journal of Africa 20100101 |
| Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke. | Cardiovascular journal of Africa 20100101 |
| Development of new anticoagulant highly honoured: Bayer's Xarelto recognised with 2010 international Prix Galien award. | Cardiovascular journal of Africa 20100101 |
| Newer antithrombotic drugs. | Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20100101 |
| Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery. | Thrombosis 20100101 |
| New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. | Thrombosis 20100101 |
| Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations. | Journal of blood medicine 20100101 |
| Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. | CADTH technology overviews 20100101 |
| Rivaroxaban in orthopedic surgery--a change of paradigm? | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20091201 |
| Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. | Internal and emergency medicine 20091201 |
| Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient? | Journal of thrombosis and haemostasis : JTH 20091201 |
| [New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy]. | Der Anaesthesist 20091201 |
| Rivaroxaban, the first oral, direct factor Xa inhibitor. | Expert opinion on pharmacotherapy 20091201 |
| Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? | Discovery medicine 20091201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091201 |
| Heparin-induced thrombocytopaenia/thrombosis: a clinicopathologic review. | East African medical journal 20091201 |
| Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? | Thrombosis and haemostasis 20091101 |
| Thromboprophylaxis after multiple trauma: what treatment and for how long? | Injury 20091101 |
| [Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians]. | Journal des maladies vasculaires 20091101 |
| New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell. | ANZ journal of surgery 20091101 |
| New antithrombotic drugs: potential for use in oncology. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091010 |
| Underestimation of the effect of bleeding in clinical trials. | Lancet (London, England) 20091003 |
| New anticoagulants and regional anesthesia. | Current opinion in anaesthesiology 20091001 |
| Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban. | Drug and therapeutics bulletin 20091001 |
| Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. | Health technology assessment (Winchester, England) 20091001 |
| [Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa]. | Revue medicale de Liege 20091001 |
| Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. | Current opinion in hematology 20090901 |
| A logical approach to surgical thromboprophylaxis. | Current opinion in hematology 20090901 |
| [Orthopedic patients with or without thrombophilia. Diagnostic, therapy and peri-operative strategies]. | Der Orthopade 20090901 |
| [New developments in antithrombotic care]. | Revue medicale de Bruxelles 20090901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090901 |
| Rivaroxaban versus enoxaparin after total knee arthroplasty. | Lancet (London, England) 20090829 |
| Rivaroxaban versus enoxaparin after total knee arthroplasty. | Lancet (London, England) 20090829 |
| Rivaroxaban versus enoxaparin after total knee arthroplasty. | Lancet (London, England) 20090829 |
| Rivaroxaban versus enoxaparin after total knee arthroplasty. | Lancet (London, England) 20090829 |
| Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. | Journal of thrombosis and haemostasis : JTH 20090801 |
| Recent developments in the use of oral anticoagulants. | Expert opinion on pharmacotherapy 20090801 |
| Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. | Journal of cardiovascular medicine (Hagerstown, Md.) 20090801 |
| Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. | Annals of surgery 20090801 |
| Factor Xa inhibitors--new anticoagulants for secondary haemostasis. | Hamostaseologie 20090801 |
| [Patients with oral anticoagulation--bridging anticoagulation in the perioperative phase]. | Hamostaseologie 20090801 |
| Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer. | Prescrire international 20090801 |
| Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Lancet (London, England) 20090704 |
| Rivaroxaban in acute coronary syndromes: too soon to know? | Lancet (London, England) 20090704 |
| New anticoagulants: focus on venous thromboembolism. | Current vascular pharmacology 20090701 |
| Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. | British journal of clinical pharmacology 20090701 |
| New anticoagulants for atrial fibrillation. | Seminars in thrombosis and hemostasis 20090701 |
| [New agents for the prevention of venous thromboembolism]. | Der Internist 20090601 |
| Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. | Expert review of cardiovascular therapy 20090601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090601 |
| 3-(3-Chloro-anilino)-1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-1-one. | Acta crystallographica. Section E, Structure reports online 20090601 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. | Lancet (London, England) 20090516 |
| The importance of VTE prevention after orthopaedic surgery. | Lancet (London, England) 20090516 |
| Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. | European journal of haematology 20090501 |
| Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. | Drug metabolism and disposition: the biological fate of chemicals 20090501 |
| In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. | Drug metabolism and disposition: the biological fate of chemicals 20090501 |
| Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. | The Journal of bone and joint surgery. British volume 20090501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090501 |
| Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor. | P & T : a peer-reviewed journal for formulary management 20090501 |
| [The new oral anticoagulant in the Netherlands]. | Nederlands tijdschrift voor geneeskunde 20090418 |
| Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. | Bioorganic & medicinal chemistry letters 20090415 |
| The direct factor Xa inhibitor rivaroxaban. | The Medical journal of Australia 20090406 |
| Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty. | Expert opinion on pharmacotherapy 20090401 |
| [New anticoagulants]. | Deutsche medizinische Wochenschrift (1946) 20090401 |
| Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? | Archives of cardiovascular diseases 20090401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| [Venous thromboembolism prophylaxis in orthopaedics and traumatology]. | Vnitrni lekarstvi 20090301 |
| [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect]. | Vnitrni lekarstvi 20090301 |
| The novel anticoagulants: entering a new era. | Swiss medical weekly 20090207 |
| [The new antithrombotics in 2009]. | Revue medicale suisse 20090204 |
| Rivaroxaban: a novel, oral, direct factor Xa inhibitor. | Pharmacotherapy 20090201 |
| New anticoagulants - towards the development of an 'ideal' anticoagulant. | VASA. Zeitschrift fur Gefasskrankheiten 20090201 |
| Laboratory monitoring of anticoagulation: where do we stand? | Seminars in thrombosis and hemostasis 20090201 |
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. | Clinical pharmacokinetics 20090101 |
| Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q). | Health and quality of life outcomes 20090101 |
| In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism. | Orthopedics 20090101 |
| New oral anticoagulants: not quite there yet. | Polskie Archiwum Medycyny Wewnetrznej 20090101 |
| Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| Use of anticoagulants in elderly patients: practical recommendations. | Clinical interventions in aging 20090101 |
| Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. | Cardiology in review 20090101 |
| Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101 |
| Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. | Vascular health and risk management 20090101 |
| The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. | Vascular health and risk management 20090101 |
| [Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. | Drugs 20090101 |
| [From old to new anticoagulants: the role of the biologist]. | Annales de biologie clinique 20090101 |
| New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness? | PharmacoEconomics 20090101 |
| A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. | PharmacoEconomics 20090101 |
| Prevention and treatment of thromboembolic events in medical patients and new anticoagulants. | Acta clinica Belgica 20090101 |
| [Pharmacology of heparins and direct anticoagulants]. | Hamostaseologie 20081201 |
| [Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| [Rivaroxaban: clinical pharmacology]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| [Perioperative venous thromboembolism prophylaxis: short review and recommendations]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| [Rivaroxaban (Xarelto): efficacy and safety]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| [Summary and perspectives. Rivaroxaban]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| [Rivaroxaban: mode of action]. | Annales francaises d'anesthesie et de reanimation 20081201 |
| Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. | Vascular health and risk management 20081201 |
| Rivaroxaban for thromboprophylaxis. | The New England journal of medicine 20081113 |
| Rivaroxaban for thromboprophylaxis. | The New England journal of medicine 20081113 |
| Rivaroxaban for thromboprophylaxis. | The New England journal of medicine 20081113 |
| Rivaroxaban for thromboprophylaxis. | The New England journal of medicine 20081113 |
| [Rivaroxaban. The first factor Xa inhibitor]. | Medizinische Monatsschrift fur Pharmazeuten 20081101 |
| [Thromboembolic disease in orthopedic surgery]. | Medicina clinica 20081101 |
| [Anaesthesia and thromboembolic disease]. | Medicina clinica 20081101 |
| [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics]. | Medicina clinica 20081101 |
| Polyphosphate as a general procoagulant agent. | Journal of thrombosis and haemostasis : JTH 20081001 |
| Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. | British journal of haematology 20081001 |
| Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events. | Journal of thrombosis and haemostasis : JTH 20081001 |
| Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. | Current medical research and opinion 20081001 |
| [Anticoagulation in atrial fibrillation]. | Hamostaseologie 20081001 |
| [Prophylaxis of venous thromboembolism]. | Hamostaseologie 20081001 |
| Rivaroxaban: future in anticoagulation practice? | Hematology (Amsterdam, Netherlands) 20081001 |
| More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement. | DukeMedicine healthnews 20081001 |
| [Always more amputations in Germany?]. | Deutsche medizinische Wochenschrift (1946) 20081001 |
| Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent. | Neurosurgery 20081001 |
| A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. | Blood 20080915 |
| Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901 |
| Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. | Thrombosis and haemostasis 20080901 |
| New developments in anticoagulation for atrial fibrillation. | Current treatment options in cardiovascular medicine 20080901 |
| Rivaroxaban: an oral direct inhibitor of factor Xa. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080815 |
| Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. | Clinical orthopaedics and related research 20080801 |
| New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. | Vascular health and risk management 20080801 |
| Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. | Lancet (London, England) 20080705 |
| Selective factor Xa inhibition for thromboprophylaxis. | Lancet (London, England) 20080705 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. | The New England journal of medicine 20080626 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. | The New England journal of medicine 20080626 |
| New anticoagulants--the path from discovery to clinical practice. | The New England journal of medicine 20080626 |
| Rivaroxaban, an oral direct factor Xa inhibitor. | Expert opinion on investigational drugs 20080601 |
| [Hematology 2008]. | Deutsche medizinische Wochenschrift (1946) 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080601 |
| Preventing venous thromboembolism through risk assessment approaches. | British journal of nursing (Mark Allen Publishing) 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080401 |
| Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. | Clinical orthopaedics and related research 20080301 |
| New anticoagulants for treatment of venous thromboembolism. | Arteriosclerosis, thrombosis, and vascular biology 20080301 |
| Update on atrial fibrillation: part I. | Clinical cardiology 20080201 |
| [New anticoagulants]. | Hamostaseologie 20080201 |
| Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. | Seminars in thrombosis and hemostasis 20080201 |
| The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. | Seminars in thrombosis and hemostasis 20080201 |
| Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. | Drug safety 20080101 |
| New oral anticoagulants in atrial fibrillation. | European heart journal 20080101 |
| Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. | Clinical pharmacokinetics 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Pharmacological strategies for inhibition of thrombin activity. | Current pharmaceutical design 20080101 |
| The top 4 advances in antithrombotic care in the last year. | Thrombosis research 20080101 |
| Brave new world: the current and future use of novel anticoagulants. | Thrombosis research 20080101 |
| Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty. | ACP journal club 20080101 |
| Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty. | ACP journal club 20080101 |
| Controversies in the antiphospholipid syndrome: can we ever stop warfarin? | Journal of autoimmune diseases 20080101 |
| New issues in oral anticoagulants. | Hematology. American Society of Hematology. Education Program 20080101 |
| Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review. | Pathophysiology of haemostasis and thrombosis 20080101 |
| Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. | Journal of clinical pharmacology 20071101 |
| Development of oral anticoagulants. | British journal of clinical pharmacology 20070901 |
| Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. | Hamostaseologie 20070901 |
| Beyond unfractionated heparin and warfarin: current and future advances. | Circulation 20070731 |
| A replacement for warfarin: the search continues. | Circulation 20070710 |
| Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. | Circulation 20070710 |
| Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. | Journal of thrombosis and haemostasis : JTH 20070701 |
| Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. | Seminars in thrombosis and hemostasis 20070701 |
| Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. | Arteriosclerosis, thrombosis, and vascular biology 20070601 |
| Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. | Thrombosis and haemostasis 20070601 |
| Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. | International journal of clinical pharmacology and therapeutics 20070601 |
| Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. | British journal of clinical pharmacology 20070401 |
| Investigational treatments of venous thromboembolism. | Expert opinion on investigational drugs 20070401 |
| In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. | Journal of thrombosis and haemostasis : JTH 20070401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070401 |
| Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. | Thrombosis and haemostasis 20070301 |
| Rivaroxaban. | Drugs of today (Barcelona, Spain : 1998) 20070301 |
| [New antitoagulants]. | Annales pharmaceutiques francaises 20070301 |
| Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. | Current opinion in investigational drugs (London, England : 2000) 20070301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070301 |
| Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. | Journal of clinical pharmacology 20070201 |
| Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. | Thrombosis research 20070101 |
| Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. | Annals of medicine 20070101 |
| Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. | Thrombosis journal 20070101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070101 |
| A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. | Circulation 20061128 |
| The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy. | Circulation 20061128 |
| Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. | Journal of clinical pharmacology 20060901 |
| Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. | Expert opinion on investigational drugs 20060801 |
| Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. | Journal of clinical pharmacology 20060501 |
| [Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches]. | Hamostaseologie 20060501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060401 |
| New oral anticoagulants show promise. | JAMA 20060215 |
| Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. | Journal of thrombosis and haemostasis : JTH 20060101 |
| Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. | European journal of clinical pharmacology 20051201 |
| BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. | Journal of thrombosis and haemostasis : JTH 20051101 |
| Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. | Clinical pharmacology and therapeutics 20051001 |
| Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. | Journal of medicinal chemistry 20050922 |
| Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. | Xenobiotica; the fate of foreign compounds in biological systems 20050901 |
| New antithrombotics in the prevention of thromboembolic disease. | European journal of internal medicine 20050801 |
| In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. | Journal of thrombosis and haemostasis : JTH 20050301 |